Signant_color_png


TrialMax eCOA:
where evidence quality begins

The design decisions made before a study starts determine whether the evidence holds up at submission. With 50+ in-house scientists available from protocol design through to submission, those decisions are better informed.

Talk with our team about your protocol, endpoint strategy and eCOA design.
image - ecoa man

eCOA is more complex
than it appears from the outside. 

Study startup delays often trace back to translation and licensing bottlenecks that appear unavoidable, but they are not. Endpoint data quality issues frequently go undetected until late in a study, when options to correct them are limited. Sites and patients disengage when the technology adds burden instead of reducing it. Protocols are sometimes simplified to fit platforms that struggle with the original design.

These are not edge cases; they are familiar patterns that show up across studies, indications, and geographies. The difference between a smooth eCOA implementation and a difficult one usually comes down to decisions made early, before the build starts, and to whether the scientific, operational, and technical foundations are in place to implement those decisions consistently across sites and countries.

How TrialMax addresses each of these, across 2,000+ studies

Whatever your protocol requires, TrialMax eCOA handles patient-reported and clinician-rated outcome collection across provisioned devices, BYOD, and web, from early-phase studies to global pivotal trials.

 

 

25+
YEARS OF EXPERIENCE

2,000+
eCOA STUDIES SUPPORTED

9K+
TRANSLATIONS

500+
SCALES

90+
COUNTRIES DEPLOYED

Supporting 25% of novel drug approvals across FDA and EMA*

When evidence quality determines whether years of research reach patients, the details matter. TrialMax brings together full-featured technology, 50+ in-house scientists, end-to-end logistics, and global infrastructure, built around your protocol.

33-1

Full-featured eCOA with no capability gaps, covering ePRO, complex ClinRO, BYOD, and provisioned devices, with built-in logic and edit checks that protect endpoint data quality.

4s (3)

50+ in-house clinical scientists guide your measurement strategy from protocol design through regulatory submission, so your endpoint data is reliable and inspection-ready.

30

In-house logistics, scale management, and 24/7 multilingual patient and site support, so your team can focus on the trial rather than troubleshooting technology.

31

2,000+ studies delivered across 90+ countries, covering every phase and every major therapeutic area, so wherever your trial runs, the infrastructure is already there.

Talk with our team about your protocol.

Tell us about your endpoints, indication, and timeline. We'll show you how Signant supports studies like yours.

REQUEST PROTOCOL REVIEW

FAQs

Do you work with our specific therapeutic area?

 Yes. TrialMax eCOA has supported implementations across all major therapeutic areas, including CNS, oncology, rare disease, cardiovascular, immunology, and more. What makes this practical is that 50+ in-house clinical scientists work alongside your team from protocol design through submission, with deep expertise in the endpoint and regulatory requirements specific to your indication. With 500+ validated scales already in the library, the measurement infrastructure for your therapeutic area is likely already in place.

Can you help if we're already using another eCOA platform?

Yes. Whether you're mid-study and needing support, evaluating a transition between studies, or running a program where different studies use different platforms, there are options. eCOA migrations and mixed-vendor environments are well-trodden ground. The conversation usually starts with your protocol and endpoints, not your current technology. 

How long does implementation typically take?

Study setup timelines depend on protocol complexity, scale reuse, and geography. With 500+ validated scales and 9,000+ translations already in the library, studies that draw on existing instruments move significantly faster than those requiring new builds. Our team can give you a realistic timeline estimate once we understand your protocol requirements.

How do you handle scale licensing and translations?

Scale licensing, copyright holder relationships, and translations are all managed end to end. The localization process follows ISPOR-recommended methodology, covering translation, back translation, reconciliation, and validation. With 500+ master English scales and 9,000+ translations already in the library, studies drawing on existing instruments can move to build without the usual translation wait, one of the most significant timeline drivers in eCOA setup. 

What does patient and site support look like during a live study?

24/7 multilingual helpdesk support for patients and sites, with agents trained on each specific live study. Over 90% of contacts are resolved on the first call. Sites can also access live web chat directly through TrialManager.

Do you support BYOD studies?

Yes. TrialMax has supported over 140 BYOD studies, including studies where BYOD data supports primary and secondary endpoints. The industry's largest BYOD study, involving 47,000+ participants, ran on TrialMax. Regulatory positioning support is also available for sponsors navigating BYOD acceptance with FDA and EMA. 

How do you ensure endpoint data quality during a live study?

Endpoint data quality is protected at multiple points. Built-in branching logic and edit checks prevent missing, ambiguous, or conflicting data at the point of entry. For sponsor and site teams, TrialManager provides near real-time compliance dashboards and patient-level oversight between visits. For studies with complex clinician-rated endpoints, PureSignal Analytics provides blinded endpoint quality monitoring with anomaly detection, so issues are caught before they affect your dataset. 


*2021–2024. Signant Health technology and services supported approximately 25% of all regulatory authorizations for new active substances in their first indications, as defined by FDA Novel Drug Approval and EMA Marketing Authorization for New Active Substance, across major global markets.

WHO IS SIGNANT HEALTH?

Signant Health Logo

Signant Health is the evidence generation company, leveraging software, deep therapeutic and scientific knowledge, and operational expertise to deliver quality evidence across traditional, virtual, and hybrid trial models. For over 25 years, 600+ sponsors and CROs of all sizes – including all Top 20 pharma – have trusted Signant’s comprehensive eClinical solutions.  Our clinical outcome assessments (eCOA, clinician ratings, cognitive testing) and wearable digital health technologies powered by Ametris provide the industry's most comprehensive evidence generation capabilities, alongside  EDC, eConsent, RTSM, supply chain management, and data quality analytics. 
Learn more at www.signanthealth.com.